Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

FACULTY

Stella Lee, MD
Associate Professor of Otolaryngology - Head & Neck Surgery
University of Pittsburgh Medical Center 
Pittsburgh, PA

Robert Naclerio, MD
Department of Otolaryngology-Head and Neck Surgery
Johns Hopkins University School of Medicine
Baltimore, MD

Mona Chitre, PharmD
Chief Pharmacy Officer & VP Integrated Clinical Strategy
Excellus Health Plan

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Mona Chitre, PharmD has no actual or potential conflicts of interest in relation to this program.
Robert Naclerio, MD  has reported the following:

Consulting: Lyra, GSK, AstraZeneca, Sanofi, Regeneron
Speaker's Bureau: Sanofi, Regeneron
Stella Lee, MD  has reported the following:
Consulting: AstraZeneca, GSK, Sanofi Regeneron, Genzyme, Genentech Novartis

The PIM planners and others have nothing to disclose. The DKBmed planners and others have nothing to disclose.

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), and the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

PHARMACY
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2705-H01-P

Type of Activity: Knowledge
Media: Internet
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 1 hour and 30 minutes

Published

April 30, 2021

Expires

April 29, 2022

TARGET AUDIENCE

This accredited activity has been designed for pharmacists, managed care pharmacists, medical directors, pharmacy directors, pharmacy benefit managers, and other formulary decision-makers involved in the management and decision-making process for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

How to Earn Credit

Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

To educate pharmacists with the most up-to-date information on treatment for chronic rhinosinusitis with nasal polyps.

EDUCATIONAL OBJECTIVES

At the conclusion of this program, the learner will be able to do the following:

• Describe the burden faced by patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
• Identify challenges present in conventional treatment options for CRSwNP.
• Evaluate the role of mAbs in CRSwNP treatment and define currently available and in-development biologics for CRSwNP.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.